Abstract: Fascin and EMMPRIN (CD 147) have a demonstrated relationship with the invasion and progression of many tumors. The aim of this study was to analyze fascin and EMMPRIN expression in non-small cell lung carcinoma and their relationship with clinicopathologic features. Fascin and EMMPRIN expression levels were investigated via the immunohistochemistry of paraffin-embedded tissues of 64 patients with non-small cell lung carcinoma, including 46 squamous cell carcinoma and 18 adenocarcinoma patients. The patients were scored on the basis of staining extent and intensity, and were then assigned a combined score. Fascin expression was present in 44 of 46 (95.6%) patients with SCC and 16 of 18 (88.8%) patients with adenocarcinoma. There was a significant correlation between fascin expression and tumor stage in the SCC and adenocarcinoma groups. EMMPRIN expression was observed in all patients with SCC (46 of 46, 100%) and 16 of 18 (88.8%) patients with adenocarcinoma. There was significant correlation between EMMPRIN expression and both tumor stage and diameter in the SCC group, but not in the adenocarcinoma group. This study revealed that high levels of fascin and EMMPRIN expression may indicate the importance of their roles in the progression of non-small cell lung carcinoma and they could be used as prognostic marker for these tumors.
Introduction
In the twentieth century, lung cancer became one of the most lethal forms of cancer worldwide. It is now the second most common malignant disease diagnosed among both men and women in the United States [1] . A variety of benign and malignant tumors develop in the lung; 90-95% are carcinomas, about 5% are bronchial carcinoids, and 2-5% are mesenchymal and other miscellaneous tumors [2] . Non-small cell lung carcinoma (NSCLC) is less often metastatic and is less responsive to chemotherapy than small cell carcinomas. Although progress in radiography and computed tomography scanning has improved the early diagnosis of lung tumors, generally the prognosis for patients remains poor because most are still diagnosed at the advanced stage, which is not curable by surgery [3] . Therefore, many molecules such as p16, CD117, TTF-1, maspin and E-cadherin have been investigated in relation to lung carcinoma's clinical and pathological features [4] [5] [6] [7] [8] .
Degradation of the extracellular matrix (ECM) around primary tumors is important for their ability to invade and metastasize [9] . EMMPRIN, also known as CD147, is a transmembrane glycoprotein of 57kD that belongs to the immunoglobulin superfamily. It has been found on the surface of tumor cells and triggers the induction of matrix metalloproteinase (MMP) [10] . MMPs have been shown to be related to degradation of the extracellular matrix, angiogenesis and tumor progression [11, 12] . Therefore, elevated EMMPRIN expression is reported for some tumors and its presence correlates with their poor clinical and pathologic features [13] [14] [15] [16] [17] .
Fascin is a globular actin cross-linking protein that is essential for cell to cell interactions, cellular migration, and cell-matrix adhesion. Its expression has been studied through the immunohistochemistry of adult human tissues; vascular endothelial cells, neuronal cells and fibroblast express fascin [18] [19] . Fascin has been defined as an important protein in carcinogenesis. It plays a role in both cellular motility and migratory changes in carcinogenesis by forming actin-based structures, and it is expressed in multiple neoplasms. Because cell motility is an important factor in the invasion and metastasis of cancers, elevated fascin expression usually correlates with high grade or metastatic tumors [20] [21] [22] [23] [24] [25] [26] .
For primary lung carcinoma, only a few studies of EMMPRIN or fascin expression have been reported [27] [28] [29] [30] . The aim of the present study was to investigate the expression of EMMPRIN and fascin by using immunohistochemistry in NSCLCs in order to interpret their relationship with each other and clinicopathological features.
Material and Methods

Patients and Tissue Samples
A total of 64 patients with NSCLC were included in this retrospective study. All specimens had been routinely fixed in formalin and processed in paraffin wax. Sections stained with H&E were re-examined, and histological type and grade of tumor were re-analyzed and recorded by two pathologists, according to the World Health Organization criteria [31] . The best samples were selected for immunohistochemistry. Histopathologically, tumor specimens were diagnosed as squamous cell carcinoma (n=46) and adenocarcinoma (n=18). The patients consisted of 59 men and 5 women whose average ages were 60.1±8.3 years at diagnosis (60±8.6 for SCCs and 60.1±7.6 for adenocarcinomas). The pathological stage was evaluated and determined under the current TNM classification [31] . Twenty-two patients were stage I, 19 were stage II, 17 were stage III and 6 were stage IV.
Immunohistochemical staining
Four micrometer sections were prepared from routinely processed paraffin blocks. Slides were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 2% hydrogen peroxide in distilled water for 10 min. For antigen retrieval, the slides were heated in a microwave for 20 min in 0.01mol/L citrate buffer solution (pH 6.0) and treated with protein block (Dako, Carpinteria, CA, USA) for 5 min at room temperature. The slides were then incubated with the primary antibody for fascin (Fascin Ab-1, Clone 55K-2, prediluted, Thermo Scientific, USA) and EMMPRIN (CD147 monoclonal antibody, Clone AB1843, 1:40, Novocastra, Newcastle upon Tyne, UK) at room temperature for 60 min, and then with the secondary antibody for 30 min. Finally, the sections were reacted in 3, 3'-diaminobenzidine (DAB), counterstained with Mayer's hematoxylin, and mounted. Appropriate positive controls were utilized, as recommended by the manufacturers.
Assessment of immunohistochemical staining
Two observers (M.K. and L.Y.) evaluated the staining levels of fascin and EMMPRIN on each section by using multihead microscopes and without prior knowledge of the clinical and pathological features of patients. Cytoplasmic staining for fascin, and cytoplasmic and membranous staining for EMMPRIN were accepted as positive. Each slide was evaluated according to staining extent and intensity. The extent of staining was calculated as the percentage of stained cells and was scored semiquantitatively, using a 0 to 4 scale for expression, where 0 = no expression, 1 = 1-25%, 2 = 26-50%, 3 = 51-75% and 4 = 76-100%. For fascin, staining intensity was categorized into three groups by comparing the staining intensity of tumor cells with that of vascular endothelial cells, where 1 = lower than endothelial cells, 2 = same as endothelial cells, and 3 = higher than endothelial cells. For EMMPRIN, staining intensity was also categorized into three groups, where 1 = weak, 2 = moderate and 3 = strong. Staining extent and intensity scores were added to give combined scores that were then allocated to 4 groups in which the categories were: 0-1, negative staining; 2-3, weak staining; 4-5, moderate staining; and 6-7, strong staining.
Statistical analysis
The Chi-Square test and Fisher's exact test were used to examine the relationships between histologic type and stage, grade, age and gender. The Mann-Whitney U test was employed to compare the expression of fascin and EMMPRIN between SCC and adenocarcinoma. Furthermore, Spearman's correlation was calculated to explore the relationship between fascin and EMMPRIN expression and tumor stage, grade, age, diameter and gender, and between each other, for both SCC and adenocarcinoma. The SPSS system (SPSS Inc., Chicago, IL, USA) was used for calculations and p-values less than 0.05 were considered significant.
Results
All patients' clinicopathological and immunohistochemical features are summarized in Tables 1 and 2 (Figure 1a, 1b) . There was significant correlation between fascin expression and tumor stage (r= 0.6, p<0.05) in the SCC group, but no correlation between fascin expression and tumor grade, age and tumor diameter (p>0.05). In the adenocarcinoma group, fascin expression was observed in 16 of 18 (88.8%) patients. One (6.2%) patient exhibited weak, 5 (31.2%) displayed moderate and 10 (62.5%) showed strong fascin expression (Figure 2a, 2b) . There was a correlation between the expression of fascin and tumor stage (r= 0.609, p<0.05), but no correlation between (Figure 3a, 3b) . There was a correlation between EMMPRIN expression and tumor stage (r= 0.786, p<0.05) and diameter (r= 0.375, p<0.05) in the SCC group. There was no correlation between EMMPRIN expression and both tumor grade and age (p>0.05). In the adenocarcinoma group, 16 of 18 (88.8%) patients exhibited EMMPRIN expression. Two (12.5%), 7 (43.7%) and 7 (43.7%) of the patients displayed weak, moderate and strong EMMPRIN expression, respectively (Figure 4 ). There was no significant correlation between EMMPRIN expression and tumor grade, stage, diameter and age (p>0.05). However, there were significant correlations between EMMPRIN and fascin expression together for the two histological types (r=0.694, p<0.05 for SCCs; r=0.702, p<0.05 for adenocarcinomas).
Discussion
Tumor cell motility, migratory ability and tumor cellstroma interactions are important for the invasion and metastatic processes of malignant tumors. For these reasons, fascin and EMMPRIN expression have been investigated for many tumors and revealed to be important for tumor progress and metastasis ability. Their presence is usually associated with poor prognostic and clinicopathological features [13] [14] [15] [16] [17] [20] [21] [22] [23] [24] [25] [26] . For lung carcinomas, there have been few studies of fascin and EMMPRIN expression [27] [28] [29] [30] . In the present study, we investigated fascin and EMMPRIN expression in SCCs and adenocarcinomas, and secondly, potential relationships with clinicopathologic features.
Pelosi et al. investigated fascin expression in 220 patients with stage I NSCLC. They found fascin expression in 196 of 220 (89%) patients. Fascin expression was correlated with high grade tumor. They also noted that diffuse fascin expression (more than a b 60% of tumor cells) and/or strong immunoreactivity are associated with shorter survival time of patients [27] . Choi et al. researched fascin expression in small (less than 3cm in diameter) peripheral lung adenocarcinomas by applying tissue microarray. They found fascin expression in 30 of 49 (61.2%) patients. High fascin expression was correlated with lymph node metastasis, lymphovascular invasion and higher tumor stage in their study [28] . In our study, we found fascin expression in 60 of 64 (93.7%) patients. Fascin expression was observed in 44 of 46 (95.6%) patients with SCC and 16 of 18 (88.8%) patients with adenocarcinoma. We found a significant correlation with fascin expression and tumor stage (p<0.05) but not with tumor grade, age and tumor diameter. Our results support the literature indicating that fascin is a valuable marker associated with poor prognostic and/or clinicopathological features. In contrast to other studies, fascin expression was relatively common in our study, having been found in 93.7% of all patients. In our view, this result may be explained by there being more advanced stage patients in our study.
EMMPRIN expression has also been reported in a few studies of lung carcinomas. Hakuma et al. investigated EMMPRIN expression in 208 NSCLC cases and detected it in 192 patients (92%). They found a correlation between EMMPRIN expression and both tumor differentiation and pT1 stage in adenocarcinomas, but not in SCCs [29] . Sienel et al. investigated EMMPRIN expression in 150 patients with NSCLC and observed it in 145 patients (96.6%). They found that membranous EMMPRIN expression correlated with reduced survival time in adenocarcinomas, but not in SCCs [30] . In our study, we found a significant relationship between EMMPRIN expression and both tumor stage and diameter in SCCs (p<0.05), but unlike some other studies, there was no significant relationship between EMMPRIN and any clinicopathologic feature in adenocarcinomas. This may have been due to low patient numbers (n=18) in the adenocarcinoma group in our study.
To our knowledge, fascin and EMMPRIN have not been investigated together in lung carcinoma before. We demonstrated correlations between fascin and EMMPRIN expression in SCCs (r=0.694, p<0.05) and adenocarcinomas (r=0.702, p<0.05).
Our study showed that fascin is expressed in advanced stage tumors of SCCs and adenocarcinomas. EMMPRIN is also associated with advanced stage tumor of SCCs, but not adenocarcinomas. In conclusion, we believe that the co-expression of fascin and EMMPRIN may play an important role in tumor progression and they can be used as a prognostic marker in NSCLCs.
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